Who is sponsoring NCT04832594?

NCT04832594 is sponsored by Karolinska University Hospital.

What drugs are being tested in NCT04832594?

Interventions in NCT04832594: AI selection for supplemental breast MRI.

What condition does NCT04832594 study?

NCT04832594 studies Breast Cancer.

Is NCT04832594 still recruiting?

NCT04832594 is currently status unknown. Last updated 5 October 2023.

Last reviewed 2023-10-05 · How we verify

NCT04832594: ScreenTrustMRI

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Using AI to Select Women for Supplemental MRI in Breast Cancer Screening

Status unknown NA Last updated 5 October 2023

What this trial tests

NA trial testing AI selection for supplemental breast MRI in Breast Cancer in 2,500 participants. Status unknown.

Timeline

1 April 2021

Primary endpoint
1 April 2023

1 July 2025

Quick facts

Lead sponsor	Karolinska University Hospital
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	screening
Enrollment	2,500
Start date	1 April 2021
Primary completion	1 April 2023
Estimated completion	1 July 2025
Sites	1 location across Sweden

Drugs / interventions tested

AI selection for supplemental breast MRI

Conditions studied

Breast Cancer — all drugs for Breast Cancer →

Sponsor

Karolinska University Hospital

Who can join

Adults 40 to 74, female only, with Breast Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a prospective clinical trial aiming to determine the ability of an AI pipeline to identify women who would benefit from supplemental MRI in terms of decreasing the number of cancers having a significantly delayed detection

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Artificial Intelligence in Oncology: Current Landscape, Challenges, and Future Directions.
Lotter W, Hassett MJ, Schultz N, Kehl KL, et al · · 2024 · cited 91× · PMID 38597966 · DOI 10.1158/2159-8290.cd-23-1199
AI-based selection of individuals for supplemental MRI in population-based breast cancer screening: the randomized ScreenTrustMRI trial.
Salim M, Liu Y, Sorkhei M, Ntoula D, et al · · 2024 · cited 33× · PMID 38977914 · DOI 10.1038/s41591-024-03093-5
Deep learning in breast imaging.
Bhowmik A, Eskreis-Winkler S. · · 2022 · cited 20× · PMID 36105427 · DOI 10.1259/bjro.20210060
Artificial Intelligence for the Diagnosis and Management of Cancers: Potentials and Challenges.
Wang M, Chang W, Zhang Y. · · 2025 · cited 1× · PMID 41200279 · DOI 10.1002/mco2.70460

Verify or expand the search:

Other recruiting trials for Breast Cancer

Currently open trials in the same condition.

NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting

Other Karolinska University Hospital trials

Trials by the same sponsor.

NCT07424690 — Catheter Ablation vs Conservative Care in Elderly Patients With Atrial Fibrillation · NA · not yet recruiting
NCT06639191 — [177Lu]Lu-AKIR001 First-in-human Study · EARLY_PHASE1 · recruiting
NCT03629977 — Timing of Renal Replacement Therapy in the Critically Ill Patients · recruiting
NCT06983197 — Iatrogenic Deficiencies in ICU Patients With Prolonged Continuous Renal Replacement Therapy · not yet recruiting
NCT06835816 — Amino Acid Supplementation in Continuous Renal Replacement Therapy · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04832594 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Karolinska University Hospital
Last refreshed: 5 October 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04832594.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing